Arcutis Biotherapeutics, Inc. (ARQT) research
Arcutis Biotherapeutics, Inc.- Sector
- Biotechnology
- Last price
- $27.78
- As of
Arcutis Biotherapeutics, Inc. (ARQT): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.
As of . Source: SEC EDGAR filings for ARQT. Method and limitations.
Share the ARQT intelligence card
See ARQT live in the terminal
Track ARQT's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live ARQT terminal, freeActive signals for ARQT
- highCONSENSUS_BUY
5 tracked funds increased ARQT this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased ARQT this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +1043% to ARQT (2026Q2)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 87% of ARQT (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 59% of ARQT (2026Q2)
FREE, NO ACCOUNT
Every signal on ARQT, as it fires
You are seeing 5 of 37 signals recorded on ARQT since 2026-06-10.
The five above landed across 2 days. The other 32 were recorded on 3 other days. 27 of the 37 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ARQT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 03969K108 · 2026Q2 | $103.6M | 0.05% | , |
| CITADEL ADVISORS LLCCUSIP 03969K108 · 2026Q2 | $30.4M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 03969K108 · 2026Q2 | $17.4M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 03969K108 · 2026Q2 | $14.8M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 03969K108 · 2026Q2 | $9.5M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 03969K108 · 2026Q2 | $1.5M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ARQT
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ARQT against its peers
ARQT's operating margin of -3.3% ranks in the 91st percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.
| Metric | ARQT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 376M USD | 33.0M USD | 81 | 17 |
| Operating margin | -3.3% | -512.9% | 91 | 15 |
| Net margin | -4.3% | -483.6% | 91 | 15 |
| Return on equity | -8.5% | -39.7% | 86 | 24 |
Peers (24): MBX, QURE, CLDX, ZLAB, ATAI, IMNM, RCUS, PHVS, VCYT, PGEN, NAMS, DNLI, NRIX, IRON, MLYS, DYN, VKTX, GRTX, LEGN, VRDN, VERA, BEAM, GRAL, IDYA. Left out: ZLDPF (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ARQT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ARQT signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ARQTand get the insider, 13F, options, and confluence read in one view.